Research Topics
Species | Russell J SchilderSummaryAffiliation: Fox Chase Cancer Center Country: USA Publications
| Collaborators
|
Detail Information
Publications
A phase 2 evaluation of irofulven as second-line treatment of recurrent or persistent intermediately platinum-sensitive ovarian or primary peritoneal cancer: a Gynecologic Oncology Group trialRussell J Schilder
Department of Medical Oncology, Fox Chase Cancer Center, Philadelphia, PA 19111, USA
Int J Gynecol Cancer 20:1137-41. 2010..Grade 4 nonhematologic toxicity was limited to one patient with anorexia and another with hypomagnesemia. Irofulven administered at this dose and schedule was well tolerated but had modest activity as a single agent...- Phase II evaluation of imatinib mesylate in the treatment of recurrent or persistent epithelial ovarian or primary peritoneal carcinoma: a Gynecologic Oncology Group StudyRussell J Schilder
Department of Medical Oncology, Fox Chase Cancer Center, 333 Cottman Ave, Philadelphia, PA 19111, USA
J Clin Oncol 26:3418-25. 2008..The association between the expression of certain markers and clinical outcome was investigated... - Phase II study of gefitinib in patients with relapsed or persistent ovarian or primary peritoneal carcinoma and evaluation of epidermal growth factor receptor mutations and immunohistochemical expression: a Gynecologic Oncology Group StudyRussell J Schilder
Department of Medical Oncology, Fox Chase Cancer Center, Philadelphia, Pennsylvania 19111, USA
Clin Cancer Res 11:5539-48. 2005.... - Phase II trial of single agent cetuximab in patients with persistent or recurrent epithelial ovarian or primary peritoneal carcinoma with the potential for dose escalation to rashRussell J Schilder
Department of Medical Oncology, Fox Chase Cancer Center, Philadelphia, PA 19111, USA
Gynecol Oncol 113:21-7. 2009..Determine if cetuximab dose escalation to induce grade 2 rash correlates with anti-tumor activity and if sera-based markers could predict likelihood of response... - Imatinib mesylate and its potential implications for gynecologic cancersHolly Dushkin
Fox Chase Cancer Center, 333 Cottman Avenue, Philadelphia, PA 19111, USA
Curr Treat Options Oncol 6:115-20. 2005.... - Pilot evaluation of high-dose carboplatin and paclitaxel followed by high-dose melphalan supported by peripheral blood stem cells in previously untreated advanced ovarian cancer: a gynecologic oncology group studyRussell J Schilder
Department of Medical Oncology, Fox Chase Center, Philadelphia, Pennsylvania 19111, USA
Gynecol Oncol 88:3-8. 2003.... - Molecular mechanisms of action of imatinib mesylate in human ovarian cancer: a proteomic analysisBhavinkumar B Patel
Division of Basic Science, Fox Chase Cancer Center, 333 Cottman Avenue, Philadelphia, Pennsylvania 19111 2497, USA
Cancer Genomics Proteomics 5:137-49. 2008..However, there is limited pre-clinical and clinical data on the molecular targets and action of imatinib in ovarian cancer... - Focus on epithelial ovarian cancerRobert F Ozols
Fox Chase Cancer Center, Philadelphia, PA 19111, USA
Cancer Cell 5:19-24. 2004 - A phase II trial of erlotinib in recurrent squamous cell carcinoma of the cervix: a Gynecologic Oncology Group StudyRussell J Schilder
Department of Medical Oncology, Fox Chase Cancer Center, Philadelphia, PA 19111, USA
Int J Gynecol Cancer 19:929-33. 2009.... - Factors associated with toxicity and response to yttrium 90-labeled ibritumomab tiuxetan in patients with indolent non-Hodgkin's lymphomaHossein Borghaei
Fox Chase Cancer Center, Philadelphia, PA, USA
Clin Lymphoma 5:S16-21. 2004.... - Phase II study of fludarabine and alpha-interferon in patients with low-grade non-Hodgkin's lymphomaGloria J Morris
Fox Chase Cancer Center, 333 Cottman Avenue, Philadelphia, PA 19111, USA
Haematologica 89:1484-91. 2004..Given the non-overlapping toxicities of IFN with those of chemotherapy and antibody-based therapeutics, there may be a role for combination therapies, especially if the biological basis of response to IFN can be elucidated... - Increased expression of the pro-protein convertase furin predicts decreased survival in ovarian cancerRobert E Page
Department of Pathology, Fox Chase Cancer Center, Philadelphia, Pennsylvania 19111, USA
Cell Oncol 29:289-99. 2007..We sought to determine if there was an association between the expression of the ubiquitously expressed PCs, furin, PACE-4, PC-5 and PC-7, and ovarian tumor progression... - RAD001 inhibits human ovarian cancer cell proliferation, enhances cisplatin-induced apoptosis, and prolongs survival in an ovarian cancer modelSeiji Mabuchi
Human Genetics Program, Fox Chase Cancer Center, Philadelphia, Pennsylvania 19111, USA
Clin Cancer Res 13:4261-70. 2007..We examined whether mTOR inhibition by RAD001 (everolimus) is therapeutically efficacious in the treatment of ovarian cancer as a single agent and in combination with cisplatin... - Evaluation of irofulven (MGI-114) in the treatment of recurrent or persistent endometrial carcinoma: A phase II study of the Gynecologic Oncology GroupRussell J Schilder
Department of Medical Oncology, Fox Chase Cancer Center, Philadelphia, PA 19111, USA
Invest New Drugs 22:343-9. 2004..Two patients experienced grade 4 hematologic adverse effects. CONCLUSION: Irofulven administered at the dose and schedule used in this trial was minimally active and resulted in significant toxicity... - Management of recurrent ovarian carcinoma: current status and future directionsLainie P Martin
Department of Medical Oncology, Fox Chase Cancer Center, Philadelphia, PA 19111, USA
Semin Oncol 36:112-25. 2009..This review will discuss the role of chemotherapy in recurrent disease, describe the various agents used in this setting, and touch on the role of biologic agents in recurrent epithelial ovarian carcinoma... - Evaluation of gemcitabine in previously treated patients with non-squamous cell carcinoma of the cervix: a phase II study of the Gynecologic Oncology GroupRussell J Schilder
Department of Medical Oncology, Fox Chase Cancer Center, 7701 Burholme Avenue, Philadelphia, PA 19111, USA
Gynecol Oncol 96:103-7. 2005..A multicenter study was conducted to evaluate the activity and toxicity of gemcitabine in patients with previously treated non-squamous cell carcinoma of the uterine cervix... - Platinum resistance: the role of DNA repair pathwaysLainie P Martin
Department of Medical Oncology, Fox Chase Cancer Center, Philadelphia, Pennsylvania 19111, USA
Clin Cancer Res 14:1291-5. 2008.... - Population pharmacokinetic and limited sampling models for carboplatin administered in high-dose combination regimens with peripheral blood stem cell supportMeiyu Shen
Department of Pharacology, Fox Chase Cancer Center, Philadelphia, PA 19111, USA
Cancer Chemother Pharmacol 50:243-50. 2002..In both cases, the models performed well when analyzed in the context of the retrospective and bootstrap analyses. Prospective studies in ovarian cancer patients should be conducted to further tailor the current models... - Novel non-cytotoxic therapy in ovarian cancer: current status and future prospectsLainie Martin
From Fox Chase Cancer Center, Philadelphia, Pennsylvania, PA 19103, USA
J Natl Compr Canc Netw 4:955-66. 2006..This article reviews novel non-cytotoxic agents that target these pathways and are currently being evaluated in ovarian carcinoma treatment... - Safety and efficacy of radioimmunotherapy with yttrium 90 ibritumomab tiuxetan (Zevalin)Hossein Borghaei
Department of Medical Oncology, Fox Chase Cancer Center, Philadelphia, PA 19111, USA
Semin Nucl Med 34:4-9. 2004..The ibritumomab tiuxetan regimen is routinely and safely given in an outpatient setting and is completed in 7 to 9 days, and is thus more convenient for patients than chemotherapy... - Long-term responses in patients with recurring or refractory B-cell non-Hodgkin lymphoma treated with yttrium 90 ibritumomab tiuxetanThomas E Witzig
Department of Internal Medicine, Division of Hematology, Mayo Clinic, Rochester, Minnesota 55905, USA
Cancer 109:1804-10. 2007..Radioimmunotherapy with radiolabeled monoclonal antibodies to CD20 produces a high response rate in patients with recurring non-Hodgkin lymphoma (NHL), but the durability of those remissions is not well defined... - Clinical activity of pertuzumab (rhuMAb 2C4), a HER dimerization inhibitor, in advanced ovarian cancer: potential predictive relationship with tumor HER2 activation statusMichael S Gordon
Arizona Cancer Center, Tuscon and Scottsdale, AZ, USA
J Clin Oncol 24:4324-32. 2006..CONCLUSION: Pertuzumab is well tolerated with a RR of 4.3% in heavily-pretreated OC patients. Further studies on pHER2 as a diagnostic are warranted... - Chronic myelogenous leukemiaEllin Berman
J Natl Compr Canc Netw 3:732-55. 2005 - A phase II study of cetuximab/paclitaxel/carboplatin for the initial treatment of advanced-stage ovarian, primary peritoneal, or fallopian tube cancerJason Konner
Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
Gynecol Oncol 110:140-5. 2008..Determine the safety and efficacy of cetuximab plus paclitaxel and carboplatin as initial treatment of stage III/IV ovarian cancer... - Hodgkin disease/lymphomaRichard T Hoppe
Stanford Comprehensive Cancer Center, USA
J Natl Compr Canc Netw 6:594-622. 2008 - Treatment with yttrium 90 ibritumomab tiuxetan at early relapse is safe and effective in patients with previously treated B-cell non-Hodgkin's lymphomaChristos Emmanouilides
Division of Hematology and Oncology, University of California Los Angeles, Los Angeles, CA 90095 1678, USA
Leuk Lymphoma 47:629-36. 2006..The quality of disease remissions obtained when (90)Y ibritumomab tiuxetan is administered after first relapse appears to be comparable with that observed with most chemotherapy regimens in first-relapse patients... - Hodgkin disease/lymphoma. Clinical practice guidelines in oncologyRichard T Hoppe
J Natl Compr Canc Netw 4:210-30. 2006 - Antilymphoma treatments given subsequent to Yttrium 90 ibritumomab tiuxetan are feasible in patients with progressive non-Hodgkin's lymphoma: a review of the literatureStephen M Ansell
Division of Hematology Mayo Clinic, 200 First St SW, Rochester, MN 55905, USA
Clin Lymphoma 5:202-4. 2004.... - Durable responses after ibritumomab tiuxetan radioimmunotherapy for CD20+ B-cell lymphoma: long-term follow-up of a phase 1/2 studyLeo I Gordon
Division of Hematology Oncology, Northwestern University Feinberg School of Medicine, 676 N St Clair, Ste 850, Chicago, IL 60611, USA
Blood 103:4429-31. 2004..Long-term responders (> 5 years) have been identified. Ibritumomab tiuxetan produces durable responses in patients with indolent and diffuse large B-cell lymphoma... - Radiation dosimetry results from a Phase II trial of ibritumomab tiuxetan (Zevalin) radioimmunotherapy for patients with non-Hodgkin's lymphoma and mild thrombocytopeniaGregory A Wiseman
Mayo Clinic, Rochester, MN 55905, USA
Cancer Biother Radiopharm 18:165-78. 2003..These correlations were not consistent across the total patient population, and therefore, could not be exploited to predict hematologic toxicity... - Ibritumomab tiuxetan radioimmunotherapy for patients with relapsed or refractory non-Hodgkin lymphoma and mild thrombocytopenia: a phase II multicenter trialGregory A Wiseman
Division of Nuclear Medicine, Mayo Clinic, Rochester, MN 55905, USA
Blood 99:4336-42. 2002..The incidence of grade 4 neutropenia, thrombocytopenia, and anemia was 33%, 13%, and 3%, respectively. Reduced-dose ibritumomab tiuxetan is safe and well tolerated and has significant clinical activity in this patient population...